<DOC>
	<DOCNO>NCT00435396</DOCNO>
	<brief_summary>This first time human ( FTIH ) study GSK Bio recombinant gB antigen evaluate safety immunogenicity CMV candidate vaccine proprietary GSK adjuvant system . The vaccine administer young male healthy subject 0 , 1 6 month . The trial ass safety immunogenicity candidate CMV vaccine . An additional secondary objective trial identify validate test able differentiate previous CMV infection CMV vaccination . Subjects follow total 2 year .</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity GSK Bio CMV Vaccine CMV-seronegative Healthy Male Adult Subjects</brief_title>
	<detailed_description>The protocol post amend reflect change consequence amendment protocol . The section impact change Key inclusion &amp; exclusion criterion . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . Male , include , 18 40 year age time first vaccination . Written inform consent obtain subject . The subject consent inform CMV HSV serostatus . Healthy subject establish medical history clinical examination enter study . Seronegative CMV . Previously complete routine childhood vaccination best knowledge . The HSV serologic status . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Any chronic drug therapy continue study period . Receipt live attenuate vaccine within 30 day study vaccine administration . Receipt medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal ) allergy treatment antigen injection within 14 day study vaccine administration . Prior receipt adjuvant component use study . Previous vaccination CMV . History recurrent herpes simplex infection ( 1 episode per year ) . Any confirm suspect immunosuppressive immunodeficient condition Hepatitis B infection hepatitis C infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness include limited diabetes mellitus thyroid disease History neurologic disorder seizures except people febrile convulsion age 5 . History malignancy Acute disease time enrollment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Hepatomegaly , right upper quadrant abdominal pain tenderness . Decreased renal function Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . History chronic alcohol consumption and/or drug abuse .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>